Clinical Trial Detail

NCT ID NCT02503722
Title Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Osimertinib + Sapanisertib

Age Groups: adult senior

No variant requirements are available.